-
1 month ago | 
theconversation.com | Nial Wheate |Jasmine Lee |Shoohb Alassadi
From May 1, the oral contraceptive Slinda (drospirerone) will be listed on the Pharmaceutical Benefits Scheme (PBS). This means the price will drop for the more than 100,000 Australian women who currently use it – from around $A320 a year to around $94. It’s the third contraceptive pill the federal government has added to the PBS this year, after Yaz and Yasmine.
-
Dec 13, 2024 | 
pubs.rsc.org | Nial Wheate
What happened to BBR3464 and where to from here for multinuclear platinum-based anticancer drugs?
The development of the trinuclear platinum(II) complex BBR3464 (also known as triplatin) in the late 1990s was meant to be a revolution in the field of platinum chemotherapy.
-
Dec 3, 2024 | 
tolerance.ca | Nial Wheate
By Nial Wheate, Professor of Pharmaceutical Chemistry, Macquarie University
The drug Visanne (also known as dienogest) is the first endometriosis treatment to be added to the Pharmaceutical Benefits Scheme (PBS) in 30 years. Endometriosis is a chronic and often debilitating condition, where tissue similar to that which normally lines the uterus grows in areas just outside the organ.
-
Dec 2, 2024 | 
theconversation.com | Nial Wheate
The drug Visanne (also known as dienogest) is the first endometriosis treatment to be added to the Pharmaceutical Benefits Scheme (PBS) in 30 years. Endometriosis is a chronic and often debilitating condition, where tissue similar to that which normally lines the uterus grows in areas just outside the organ. It affects around one in seven Australian women and there is currently no cure. Why has the government decided to subsidise Visanne? Here’s how this daily tablet works and who it might help.
-
Nov 21, 2024 | 
medicalxpress.com | Nial Wheate |Jasmine Lee |Tina Hinton
Australia's drug regulator has issued a over the medicine Phenergan and related products containing the antihistamine drug promethazine. The Therapeutic Goods Administration said the over-the-counter products should not be given to children under six due to concerns of serious side effects including hyperactivity, aggression and hallucination. Breathing can also become slow or shallow, which can be fatal.
-
Nov 20, 2024 | 
theconversation.com | Nial Wheate |Jasmine Lee |Tina Hinton
Australia’s drug regulator has issued a over the medicine Phenergan and related products containing the antihistamine drug promethazine. The Therapeutic Goods Administration said the over-the-counter products should not be given to children under six due to concerns of serious side effects including hyperactivity, aggression and hallucination. Breathing can also become slow or shallow, which can be fatal.
-
Sep 12, 2024 | 
hashtag.net.au | Nial Wheate
Common medicines used to treat conditions including heartburn, reflux, indigestion and stomach ulcers may be the subject of a class action lawsuit in Australia. Lawyers are exploring whether long-term use of these over-the-counter and prescription drugs are linked to stomach cancer or kidney disease. The potential class action follows the settlement of a related multi-million dollar lawsuit in the United States.
-
Sep 12, 2024 | 
medicalxpress.com | Nial Wheate |Joanna Harnett |Wai-Jo Jocelin Chan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:Common medicines used to treat conditions including heartburn, reflux, indigestion and stomach ulcers may be the subject of a class action lawsuit in Australia. Lawyers are exploring whether long-term use of these over-the-counter and prescription drugs are linked to stomach cancer or kidney disease.
-
Sep 12, 2024 | 
theconversation.com | Nial Wheate |Joanna Harnett |Wai-Jo Jocelin Chan
Common medicines used to treat conditions including heartburn, reflux, indigestion and stomach ulcers may be the subject of a class action lawsuit in Australia. Lawyers are exploring whether long-term use of these over-the-counter and prescription drugs are linked to stomach cancer or kidney disease. The potential class action follows the settlement of a related multi-million dollar lawsuit in the United States.
-
Aug 28, 2024 | 
agedcareinsite.com.au | Nial Wheate |Tina Hinton
Nial Wheate, Macquarie University and Tina Hinton, University of SydneyAustralia currently finds itself in the unusual position of being both in an opioid epidemic and experiencing a shortage of these critical medicines. The Therapeutic Goods Administration has placed eight oral morphine products on its shortage list. It doesn’t expect supply for these products to be resolved until around October or November this year.
